Maplight Therapeutics (MPLT) – Investment Analysts’ Weekly Ratings Changes

Maplight Therapeutics (NASDAQ: MPLT) recently received a number of ratings updates from brokerages and research firms:

• 4/8/2026 – Maplight Therapeutics is now covered by Needham & Company LLC. They set a “buy” rating and a $37.00 price target on the stock.
• 4/7/2026 – Maplight Therapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.
• 3/21/2026 – Maplight Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/19/2026 – Maplight Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $35.00 price target on the stock.

Insider Activity at Maplight Therapeutics

In related news, Director Robert C. Malenka sold 11,264 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $18.42, for a total transaction of $207,482.88. Following the sale, the director owned 325,795 shares of the company’s stock, valued at $6,001,143.90. This trade represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director George Pavlov acquired 9,920 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were bought at an average cost of $17.86 per share, for a total transaction of $177,171.20. Following the purchase, the director owned 25,000 shares of the company’s stock, valued at approximately $446,500. The trade was a 65.78% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 39,124 shares of company stock valued at $693,846 and have sold 74,612 shares valued at $1,368,065.

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.